Application 207971
- Type
- ANDA
- Sponsor
- STRIDES PHARMA
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | FINGOLIMOD | FINGOLIMOD | CAPSULE;ORAL | 0.5MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A207971-001 | FINGOLIMOD HYDROCHLORIDE | FINGOLIMOD HYDROCHLORIDE | EQ 0.5MG BASE | CAPSULE / ORAL | 2020-06-29 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A207971-001 | FINGOLIMOD HYDROCHLORIDE | EQ 0.5MG BASE | CAPSULE / ORAL | 2020-06-29 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| FINGOLIMOD | FINGOLIMOD | Quallent Pharmaceuticals Health LLC | 5434bd4a-2610-0e17-4f14-513ff1cbb822 | 2026-06-10 | Warnings, Adverse reactions | FINGOLIMOD FINGOLIMOD |
| Fingolimod | FINGOLIMOD | CivicaScript LLC | e1960f9b-f739-452c-b167-245551bf3690 | 2026-05-25 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Alembic Pharmaceuticals Limited | d0538769-3cec-4cf2-97e5-41e79599c181 | 2026-04-30 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Alembic Pharmaceuticals Inc. | 54bf842e-9772-424d-87b2-61863b6f4b19 | 2026-04-27 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD HYDROCHLORIDE | Ascend Laboratories, LLC | 0f638feb-6986-41e4-8f9c-2e6b84a5bb44 | 2026-03-27 | Warnings, Adverse reactions | Fingolimod |
| fingolimod | FINGOLIMOD | Glenmark Pharmaceuticals Inc., USA | 8fe14efd-8f61-40db-9069-bb17daf3261a | 2026-01-31 | Warnings, Adverse reactions | fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD | AvKARE | 1171df44-48b4-6ef2-e063-6294a90aa121 | 2026-01-13 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| FINGOLIMOD | FINGOLIMOD | Aurobindo Pharma Limited | d6301307-55c6-4b91-a505-ff93c865f859 | 2026-01-01 | Warnings, Adverse reactions | FINGOLIMOD FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Camber Pharmaceuticals, Inc. | c3199508-3d6a-4e44-96f0-bbde9969edcb | 2025-12-18 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| FINGOLIMOD | FINGOLIMOD | Biocon Pharma Inc. | 550a5fa3-94a4-0b55-9cb5-c0178acfe319 | 2025-11-26 | Warnings, Adverse reactions | FINGOLIMOD FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Teva Pharmaceuticals, Inc. | d9aa1078-fd72-47ef-84b2-2e1ad17b12a2 | 2025-11-01 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Dr. Reddy's Laboratories Inc | 56badc2a-6747-9284-300e-bf072eb072ed | 2025-10-22 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Apotex Corp. | a545c6fc-7006-52c2-f476-34e9801ac04f | 2025-09-11 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Sun Pharmaceutical Industries, Inc. | b228dac8-b07d-424d-b23b-a03573517c54 | 2025-09-05 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Zydus Pharmaceuticals USA Inc. | e738dbd9-f4cc-49a0-98ce-73dd0c3ff3b3 | 2025-09-02 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
| Fingolimod | FINGOLIMOD | Zydus Lifesciences Limited | 5a0319b4-4bc6-4564-9687-9cfd5c1b23a8 | 2024-11-30 | Fingolimod FINGOLIMOD | |
| fingolimod | FINGOLIMOD HCL | Rising Pharma Holdings, Inc. | 99e7daf4-ea90-5e47-e053-2a95a90ac1b7 | 2024-11-04 | Warnings, Adverse reactions | fingolimod |
| FINGOLIMOD | FINGOLIMOD | Solco Healthcare US, LLC | 6c0faf2b-21fb-4830-bb78-5f2dbceb2c82 | 2024-07-31 | Warnings, Adverse reactions | FINGOLIMOD FINGOLIMOD |
| Fingolimod | FINGOLIMOD | XLCare Pharmaceuticals Inc. | c5402dd1-c496-405d-9cae-07ccf184339c | 2024-06-20 | Warnings, Adverse reactions | Fingolimod FINGOLIMOD |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 64380-776 | FINGOLIMOD | fingolimod | Strides Pharma Science Limited | ANDA | Current |